05/26/2017

FDA approved ZYKADIA® (ceritinib) for patients with NSCLC

The FDA has granted regular approval to ZYKADIA® (ceritinib) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

For more information, click here.